3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Neoplasms, Plasma Cell
1
Neoplasms
1
Lymphoma
1
Leukemia
1
Infections
1
Hematologic Neoplasms
1
Agammaglobulinemia
1
Interventions
venetoclax
27
Cyclophosphamide
18
Azacitidine
13
fludarabine
12
ibrutinib
10
Busulfan
10
fludarabine phosphate
9
Rituximab
8
Mycophenolic Acid
8
Methotrexate
8
Cytarabine
8
Whole-Body Irradiation
7
Peripheral Blood Stem Cell Transplantation
7
Clofarabine
7
Therapeutics
6
Melphalan
6
Antilymphocyte Serum
6
obinutuzumab
5
Tacrolimus
5
Surveys and Questionnaires
5
Stem Cell Transplantation
5
Mesna
5
Exercise
5
Cyclosporine
5
vosaroxin
4
trametinib
4
thymoglobulin
4
ruxolitinib
4
ponatinib
4
Trimethoprim, Sulfamethoxazole Drug Combination
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
Clavulanic Acid
×
Other hematologic neoplasm
×
Clear all
NCT05678621
2024-04-19
RATIONALISE
Monash University
Phase 2/3
Recruiting
300 enrolled